Acute
Navigation Links
Acute at medicine technology
EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...
HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.today presented preliminary results from a pilot Phase 3 trial ofKW-3902, an adenosine A1 receptor antagonist in development for thetreatment of patients with acute congestive heart failure (CHF),that indicate a strong trend toward efficacy for the 30 milligramdose. Patients treated with KW-3902 experienced a higher rate ofi...
- Cipralex Better Tolerated and at Least as Effective inLong-Term Treatment H. Lundbeck A/S announces new study data published today in thejournal Current Medical Research and Opinion, demonstrating thatCipralex(R) (escitalopram) was superior to duloxetine in the acutetreatment of patients with major depressive disorder (MDD)...
NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. and PAION AG today announced topline results ofthe DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with thecompound Desmoteplase. The Phase III study was designed toinvestigate the improvement of clinical outcome in patients withacute ischemic stroke treated with Desmoteplase within 3 to 9 hoursafter onset of...
PAION AG and US Partner Forest Laboratories, Inc. TodayAnnounced the Top Line Results of the DIAS-2 (Desmoteplase In AcuteIschemic Stroke) Study with the Compound Desmoteplase Aachen (Germany), May 31st, 2007 - PAION AG (Frankfurt StockExchange, Prime Standard: PA8) and its US partner ForestLaboratories, Inc. (NYSE: FRX) today announced topline results ofthe DIAS-2 (Desmoteplase In...
ANAHEIM, Calif., May 19, 2007 /PRNewswire/ -- Data presentedtoday at a major medical meeting found that Levaquin (levofloxacin)750 mg tablets administered once-daily for five days is aseffective as standard therapy of ciprofloxacin (400/500 mg) for 10days for the treatment of complicated urinary tract infections(cUTI) and acute pyelonephritis (AP). Ortho-McNeil, Inc., the company t...
NICE Appraisal Committee concludes that alteplase is clinicallyand cost effective INGELHEIM/Germany, 14 May 2007 – A new clinical appraisalpublished by the National Institute for Health and ClinicalExcellence (NICE) in the UK has recommended the use of alteplasefor the treatment of patients with acute ischaemic stroke, based onits clinical and cost effectiveness...
The research, done in collaboration with the Centro deInvestigación Médica Aplicada (CIMA) at theUniversity of Navarra, Pamplona, Spain, is being presented atPorphyrins and Porphyrias Congress, Rotterdam, the Netherlands. AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam MolecularTherapeutics BV (AMT), a leader in the field of human gene therapy,will today present...
Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by aSignificant 43% in Acute Ischemic Stroke Patients Treated WithClexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced the publication of the PREVAIL (Preventionof VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial inthe April 21st issue of The Lancet. The results of th...
Initial Analysis Shows Statistically Significant Changes inAgitation Levels With 10 mg AZ-004 PALO ALTO, Calif., March 26, 2007 /PRNewswire-FirstCall/ --Alexza Pharmaceuticals, Inc. today announced positive initialresults from its Phase IIa clinical trial of AZ-004 (Staccato(R)loxapine) in schizophrenic patients with acute agitation. The 10 mgdose of AZ-004 met the primary endpoint of the...
Focus Must Remain on the Millions Still Suffering from ChronicHepatitis B and C NEW YORK, March 21, 2007 /PRNewswire/ -- The Centers for DiseaseControl and Prevention (CDC) has reported that significant declinein the rates of new acute hepatitis infections in the United Statesin the last 10 years, reflecting the success of hepatitis A and Bvaccination programs. The American Liver Foundati...
Results expand potential application of key product inAM-Pharma's pipeline BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced positiveresults in patients with Acute Renal Failure. The patients involvedwere a subgroup of a Phase IIa trial with Alkaline Phosp...
Proof of Concept in Mice Transgenic for Human TNFa LAUSANNE, Switzerland, March 12, 2007 /PRNewswire/ -- DebiopharmGroup (Debiopharm), a global independent biopharmaceuticaldevelopment company specialising in oncology and serious medicalconditions, announces the presentation of preclinical results thatvalidate the mechanism of action of Debio-0512 as an anti-TNFatherapeutic vaccine, that...
SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-EdenPharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it wasinformed late Wednesday, March 07, 2007, by the Department ofHealth & Human Services (HHS) that NEUMUNE(R), the Company'sproduct candidate for the treatment of Acute Radiation Syndrome(ARS) was found technically unacceptable and was no longer in thecompetitive range for th...
HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.today presented preliminary results from a pilot Phase 3 trial ofKW-3902, an adenosine A1 receptor antagonist in development for thetreatment of patients with acute congestive heart failure (CHF),that indicate a strong trend toward efficacy for the 30 milligramdose. Patients treated with KW-3902 experienced a higher rate ofi...
NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., aprivately held specialty pharmaceutical company, today announcedpositive results from an initial Phase I study of NP101SmartRelief, a novel treatment for acute migraine being developedby NuPathe. NP101 combines NuPathe's SmartRelief(TM) proprietaryiontophoretic transdermal technology with sumatriptan, the mostwidely prescri...Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
COPENHAGEN, June 4, 2007-A new study published today in thejournal Current Medical Research and Opinion showed thatCipralex® (escitalopram) was superior to Cymbalta®(duloxetine) in the acute treatment of patients with majordepressive disorder (MDD) and was at least as efficacious inlong-term treatment. The study directly compared Cipralex® (anallosteric serotonin reuptake inh...- Cipralex Better Tolerated and at Least as Effective inLong-Term Treatment H. Lundbeck A/S announces new study data published today in thejournal Current Medical Research and Opinion, demonstrating thatCipralex(R) (escitalopram) was superior to duloxetine in the acutetreatment of patients with major depressive disorder (MDD)...
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with epratuzumab plus standardchemotherapy is feasible...NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. and PAION AG today announced topline results ofthe DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with thecompound Desmoteplase. The Phase III study was designed toinvestigate the improvement of clinical outcome in patients withacute ischemic stroke treated with Desmoteplase within 3 to 9 hoursafter onset of...
PAION AG and US Partner Forest Laboratories, Inc. TodayAnnounced the Top Line Results of the DIAS-2 (Desmoteplase In AcuteIschemic Stroke) Study with the Compound Desmoteplase Aachen (Germany), May 31st, 2007 - PAION AG (Frankfurt StockExchange, Prime Standard: PA8) and its US partner ForestLaboratories, Inc. (NYSE: FRX) today announced topline results ofthe DIAS-2 (Desmoteplase In...
ANAHEIM, Calif., May 19, 2007 /PRNewswire/ -- Data presentedtoday at a major medical meeting found that Levaquin (levofloxacin)750 mg tablets administered once-daily for five days is aseffective as standard therapy of ciprofloxacin (400/500 mg) for 10days for the treatment of complicated urinary tract infections(cUTI) and acute pyelonephritis (AP). Ortho-McNeil, Inc., the company t...
NICE Appraisal Committee concludes that alteplase is clinicallyand cost effective INGELHEIM/Germany, 14 May 2007 – A new clinical appraisalpublished by the National Institute for Health and ClinicalExcellence (NICE) in the UK has recommended the use of alteplasefor the treatment of patients with acute ischaemic stroke, based onits clinical and cost effectiveness...
The research, done in collaboration with the Centro deInvestigación Médica Aplicada (CIMA) at theUniversity of Navarra, Pamplona, Spain, is being presented atPorphyrins and Porphyrias Congress, Rotterdam, the Netherlands. AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam MolecularTherapeutics BV (AMT), a leader in the field of human gene therapy,will today present...
Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by aSignificant 43% in Acute Ischemic Stroke Patients Treated WithClexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced the publication of the PREVAIL (Preventionof VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial inthe April 21st issue of The Lancet. The results of th...
Initial Analysis Shows Statistically Significant Changes inAgitation Levels With 10 mg AZ-004 PALO ALTO, Calif., March 26, 2007 /PRNewswire-FirstCall/ --Alexza Pharmaceuticals, Inc. today announced positive initialresults from its Phase IIa clinical trial of AZ-004 (Staccato(R)loxapine) in schizophrenic patients with acute agitation. The 10 mgdose of AZ-004 met the primary endpoint of the...
Focus Must Remain on the Millions Still Suffering from ChronicHepatitis B and C NEW YORK, March 21, 2007 /PRNewswire/ -- The Centers for DiseaseControl and Prevention (CDC) has reported that significant declinein the rates of new acute hepatitis infections in the United Statesin the last 10 years, reflecting the success of hepatitis A and Bvaccination programs. The American Liver Foundati...
Results expand potential application of key product inAM-Pharma's pipeline BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced positiveresults in patients with Acute Renal Failure. The patients involvedwere a subgroup of a Phase IIa trial with Alkaline Phosp...
Proof of Concept in Mice Transgenic for Human TNFa LAUSANNE, Switzerland, March 12, 2007 /PRNewswire/ -- DebiopharmGroup (Debiopharm), a global independent biopharmaceuticaldevelopment company specialising in oncology and serious medicalconditions, announces the presentation of preclinical results thatvalidate the mechanism of action of Debio-0512 as an anti-TNFatherapeutic vaccine, that...
SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-EdenPharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it wasinformed late Wednesday, March 07, 2007, by the Department ofHealth & Human Services (HHS) that NEUMUNE(R), the Company'sproduct candidate for the treatment of Acute Radiation Syndrome(ARS) was found technically unacceptable and was no longer in thecompetitive range for th...
Other TagsGolgiNeutrophilOther Contentsvasodilationdiseasesdiseasesdiseasesdiseasesdiseasesdiseasesdiseasesdiseasesdiseasesdiseasesvegetarianismspasmspasmvasectomyvasectomyvasectomyvasoconstrictionrhinitisrhinitisrhinitisvasomotor
AmikaIntegrinsChaperoneZonulaViraffinityGolgiCaveolinBasophilNeutrophilGuanosineIsotetrandrineSuraminBoekelZymoclean
(Date:8/20/2008)...iate Professor of Neuroscience at LSU Health Scien... of the only naturally occurring fatty acids in t... receptors originally identified as the targets of... help to protect brain cells from neurodegenerativ...shed in the August 15, 2008 issue of the Journal ...
(Date:8/20/2008)...have found a way to convert ethanol and other biof...alyst makes hydrogen from ethanol with 90 percent ...nsive ingredients. , Umit Ozkan, professor of ch...University, said that the new catalyst is much les... world, because it does not contain precious metal...
(Date:8/19/2008)...esearchers began studying the environmental fate o...energy industry for decades, they did not expect t... capable of converting hydrocarbons into natural g...king processknown as anaerobic hydrocarbon metabol... from older, more mature oil reservoirs like those...
(Date:8/19/2008)...ional team led by NYU Cancer Institute have identi...n of cilia, which are found on virtually all matur...ction. , The new report, published this week b...d publication of the open-access online edition, d...ate the formation of primary cilia. The study led ...
Breaking Biology News(10 mins):LSUHSC research reports new method to protect brain cells from diseases like Alzheimer's 2A better way to make hydrogen from biofuels 2A better way to make hydrogen from biofuels 3OU researchers isolate microorganisms that convert hydrocarbons to natural gas 2OU researchers isolate microorganisms that convert hydrocarbons to natural gas 3NYU scientists identify critical protein complex in formation of cell cilia 2Sigma Aldrich Amends Credit Facility and Expands Commercial Paper Program 14667 1Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries 14664 1Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries 14664 2PCMA Statement on Comparative Effectiveness 14663 1National Religious Coalition Deeply Concerned by HHS Secretarys Disregard for Womens Reproductive Health 14661 1National Religious Coalition Deeply Concerned by HHS Secretarys Disregard for Womens Reproductive Health 14661 2[0] LSUHSC research reports new method to protect brain cells from diseases like Alzheimer's[0] A better way to make hydrogen from biofuels[0] OU researchers isolate microorganisms that convert hydrocarbons to natural gas[0] NYU scientists identify critical protein complex in formation of cell cilia
(Date:8/20/2008)...covery -- that calorie-burning brown fat can be pr...in mice -- raises the prospect of new ways to figh...-Farber Cancer Institute. , Reporting in the Aug...s demonstrated that brown fat, which is known as t...s calories and releases energy, unlike "bad" white...
(Date:8/20/2008).../PRNewswire-USNewswire/ -- Yesterday evening,Cong...ron Hospital after,suffering an aneurysm while dri...esent time Rep. Tubbs Jones, condition has stabili... Tuesday,s condition followed a full day of activ...lectoral reform, scheduled for September 4, 2008,a...
(Date:8/20/2008)...op entertainers helps introduce new light beer, ...LAS, Aug. 20 /PRNewswire/ -- Multi-platinum singer...rinker?, Everyone knows about Jessica Simpson,s d...rican beauty and world-renowned entertainer has a,...oices. But she also makes,those smart choices with...
(Date:8/20/2008)... As the costs of healthcare and gas rise, older A...emselves worrying about how they can afford their ...D.C. (PRWEB) August 20, 2008 -- As the costs of he...d income and resources also find themselves worryi... ,"I have Medicare but I can,t afford prescri...
Breaking Medicine News(10 mins):Health News:Making 'good' fat from muscle and vice versa 2Health News:Making 'good' fat from muscle and vice versa 3Health News:Jessica Simpson Lends Healthy Image for Drink Smart Campaign 2Health News:Jessica Simpson Lends Healthy Image for Drink Smart Campaign 3Health News:Meals or Meds? BenefitsCheckUp Helps Older People Struggling with Food Costs 2| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |